Marksans Pharma achieved its strongest quarterly performance in Q2 FY27, reporting record revenue from operations at ₹940 crore, a 30.5% year-on-year growth. Profitability also saw significant improvement, with EBITDA increasing by 48.3% to ₹214 crore and an expanded EBITDA margin of 22.8%. The company highlighted diversified growth across Europe, the UK, and North America, underscoring a robust business model.
Marksans Pharma Reports Record Q2 FY27 Performance
Marksans Pharma has announced its financial results for the second quarter of FY27, reporting its strongest quarterly performance to date. The company’s revenue from operations reached a record high of ₹940 crore, representing a substantial 30.5% year-on-year growth and an 11.8% sequential increase.
Profitability and Margin Expansion
The impressive revenue growth was accompanied by a marked improvement in profitability. EBITDA saw a significant increase of 48.3% year-on-year, reaching ₹214 crore. The company’s EBITDA margin expanded by 274 basis points to 22.8%, exceeding its 20%-21% guidance range. This performance was attributed to strong underlying business growth, effective cost management, and geographic diversification.
Geographically Diversified Growth
Marksans Pharma emphasized its geographically diversified business model, with strong momentum observed across Europe, the UK, and North America. North America continues to be the largest market, contributing 44.8% of revenue (₹421 crore), while the UK and Europe together accounted for 43% (₹405 crore). Australia and New Zealand also showed strong traction, with revenue growing by 64% to ₹101 crore.
Underlying Business Strength
Excluding the contribution from QliniQ, the company’s underlying business delivered a growth of approximately 25%. This sustained healthy profitability despite higher freight and input costs provides confidence in the company’s strategic investments and their translation into sustainable growth. The company is actively pursuing opportunities from a position of financial strength, with a strong cash generation and net cash balance.
Future Outlook and Strategy
Looking ahead, Marksans Pharma plans to deepen its presence in existing markets, scale its European platform, expand its product portfolio, and selectively enter new markets. The company is also exploring expansion of its manufacturing capabilities in India, aiming to increase capacity to 16 billion units per annum, with potential acquisitions or plant expansions planned over the next 12-18 months.
Source: BSE
